Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ACS chemical neuroscience molecule spotlight on Saphris.

ABSTRACT: On August 14th, 2009, for the first time, the FDA has approved a psychotropic medication for two indications simultaneously. Saphris (asenapine) is a multitarget atypical antipsychotic medication approved to treat adults with schizophrenia and bipolar I disorder.

SUBMITTER: Hopkins CR

PROVIDER: S-EPMC3368668 | biostudies-other | 2010 Apr

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

ACS chemical neuroscience molecule spotlight on Saredutant.

Project description:Saredutant (SR48968), a potentially novel treatment option for major depressive disorders (MDD) and generalized anxiety disorder (GAD), is a drug from Sanofi-Aventis currently in phase III clinical trials. MDD is a common mental disorder that affects 121 million people worldwide, nearly 4% of the adult population (www.who.int/mental_health/management/depression/definition/en/). MDD continues to be one of the leading causes of disability with more than three quarters of the diagnosed cases having effective treatments available (www.who.int/mental_health/management/depression/definition/en/). However, even though MDD affects a large portion of the population, effective treatment options with low incidence of adverse events remain a major concern for the pharmaceutical industry. Adverse events (GI side effects1, weight gain, somnolence/insomnia, etc. (Demyttenaere K. (2003) Risk factors and predictors of compliance in depressionEur. Neuropshychopharm.13S69-S75)) from the typical treatments remain the major reason for premature stopping or poor compliance of treatment. New treatments to the market must bear in mind these adverse events, and the pharmaceutical industry is currently looking for drugs with new mechanisms of action and those that are better tolerated.

| S-EPMC3368631 | biostudies-other

ACS chemical neuroscience molecule spotlight on Valdoxen.

Project description:A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT(2C) receptor.

| S-EPMC3368641 | biostudies-other

ACS chemical neuroscience molecule spotlight on Lorcaserin.

Project description:Lorcaserin (APD-356) is the first in a new class of selective serotonin 5-hydroxytryptamine(2C) (5-HT(2C)) receptor agonists. On December 22, 2009, the compound's developer (Arena Pharmaceuticals) submitted an NDA to the FDA for approval for weight management.

| S-EPMC3368635 | biostudies-other

ACS chemical neuroscience molecule spotlight on dimebon.

Project description:Dimebon (latrepirdine) is an antihistamine drug that has been used clinically in Russia since the early 1980s and is being studied jointly by Pfizer and Medivation for patients with Alzheimer's disease. The results from a pivotal Phase 3 clinical trial (CONNECTION) showed that Dimebon (latrepirdine) failed to meet its coprimary or secondary efficacy end points.

| S-EPMC3368692 | biostudies-other

ACS chemical neuroscience molecule spotlight on savella.

Project description:Savella (milnacipran), a selective serotonin and noradrenaline reuptake inhibitor, was approved by the FDA on January 14th, 2009, for the treatment of fibromyalgia.

| S-EPMC3368674 | biostudies-other

ACS chemical neuroscience molecule spotlight on RG1678.

Project description:RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.

| S-EPMC3369722 | biostudies-other

ACS chemical neuroscience molecule spotlight on contrave.

Project description:Contrave is an investigational fixed-dose combination drug of naltrexone and bupropion currently in Phase III clinical trials for the treatment of obesity. Orexigen Therapeutics, Inc. has demonstrated efficacy of their product and is currently addressing FDA safety concerns and deciding future actions.

| S-EPMC3369782 | biostudies-other

ACS chemical neuroscience molecule spotlight on Qnexa.

Project description:Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical trials for the treatment of obesity. Vivus, Inc. has demonstrated efficacy of their product and are currently addressing FDA safety concerns with the possibility of a New Drug Application (NDA) resubmission.

| S-EPMC3369742 | biostudies-other

ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).

Project description:Semagacestat (LY450139) is a novel γ-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.

| S-EPMC3368681 | biostudies-other

ACS chemical neuroscience molecule spotlight on BMS-708163.

Project description:BMS-708163 is a novel, sulfonamide containing γ-secretase inhibitor from Bristol-Myers Squibb Co. currently in Phase II clinical trials for the treatment of Alzheimer's disease (AD).

| S-EPMC3369796 | biostudies-other

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data